Mitapivat and Baxdrostat: Interaction Details
- Mitapivat
- PyrukyndAqvesme
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Mitapivat and Baxdrostat interaction:
Baxdrostat
We don't have a drug information page for Baxdrostat yet. Have a question about Baxdrostat? Ask a pharmacist, free →
What Happens When You Take Mitapivat With Baxdrostat
What can happen when they are taken together (rated Moderate)
Reduced baxdrostat exposure and reduced of baxdrostat
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
When baxdrostat is taken together with strong or moderate , baxdrostat exposure falls, and this decline may weaken its efficacy. The therapeutic response to baxdrostat should be checked more often if a moderate or strong CYP3A is used at the same time.1
The Mitapivat and Baxdrostat Interaction, Explained
Mitapivat (used for certain types of hemolytic anemia) may act as a mild to moderate , which means it can speed up how fast your liver breaks down certain medicines. Baxdrostat (a blood pressure medicine) is cleared this way. So taking both could lower the amount of baxdrostat in your body, and it might not control your blood pressure as well.
This is based on theory, not on a study of these two drugs together. Keep taking both as prescribed. Your care team can check your blood pressure more often and adjust your plan if needed.
Mechanism: Mitapivat is a (weak to moderate by label). Baxdrostat is by CYP3A, so may increase its and lower exposure (, ). Baxdrostat is not a that needs CYP3A activation, so the direction is reduced effect.
- Effect: reduced baxdrostat exposure and possible loss of antihypertensive .
- Evidence: theoretical, extrapolated from the class effect of moderate/strong CYP3A . No dedicated study with mitapivat is documented.
- Onset: unspecified.
- Severity: moderate.
- Management: monitor baxdrostat's therapeutic effect (e.g., blood pressure) more frequently. Dose may need individualized adjustment by the care team.
See the 1 reference behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Mitapivat and Baxdrostat Interact
The likely mechanism
of -mediated of baxdrostat
How to Manage the Mitapivat and Baxdrostat Interaction
Your care team can manage this by keeping a closer eye on how well baxdrostat is working.
- Keep taking both medicines as prescribed. Do not change or stop either one on your own.
- Expect your team to monitor baxdrostat's effect more often, such as checking your blood pressure.
- Tell your pharmacist or prescriber if your readings rise or you feel different after starting mitapivat.
- Your team may individualize your baxdrostat dose if needed.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Mitapivat or Baxdrostat need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
Mitapivat and Baxdrostat: Common Questions
How serious is the Mitapivat and Baxdrostat interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How is the Mitapivat and Baxdrostat interaction managed?
Your care team can manage this by keeping a closer eye on how well baxdrostat is working. Keep taking both medicines as prescribed. Do not change or stop either one on your own. Expect your team to monitor baxdrostat's effect more often, such as checking your blood pressure. Tell your pharmacist or prescriber if your readings rise or you feel different after starting mitapivat. Your team may indiv… Management is individual — always follow your own care team's guidance.
Does taking Mitapivat and Baxdrostat at different times of day help?
No. Taking them at different times of day does not prevent this one. Mitapivat speeds up , an enzyme that breaks down baxdrostat, so baxdrostat can be cleared faster. That change lasts while mitapivat is being taken and can continue for a while after the last dose.
Your pharmacist or prescriber can tell you how they will manage it.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
Ask About the Mitapivat and Baxdrostat Interaction
Ask in your own words about taking Mitapivat and Baxdrostat together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (1)
- Product Information: BAXFENDY™ oral tablets, baxdrostat oral tablets. AstraZeneca Pharmaceuticals LP, Wilmington, DE, 2026. DailyMed
Other Serious Interactions of Mitapivat and Baxdrostat
Also serious with Mitapivat
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Mitapivat
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- Vitamin EModerate
- GingerModerate
- TurmericModerate
- Black PepperModerate
- GrapeModerate
- + 151 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring.
- Moderate Can be significant — usually manageable with monitoring. This interaction.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.